6986.TWO HeXun Biosciences Co., Ltd.
- Market cap
- TWD 2.05B
- P/E
- 16.0x
- P/B
- 2.06x
- ROE
- 12.3%
- Dividend yield
- 0.46%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6986.TWO undervalued?
Graham number6986.TWO trades 21.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
HeXun Biosciences Co., Ltd. fundamental analysis
No fundamental analysis for HeXun Biosciences Co., Ltd. yet.
HeXun Biosciences Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About HeXun Biosciences Co., Ltd.
HeXun Biosciences Co., Ltd. engages in the research and development of stem cell drug development and cardiovascular disease treatments in Taiwan. It provides contract manufacturing; commissioned inspection; aseptic filling; and consulting services. The company was founded in 2019 and is based in Taoyuan City, Taiwan.
Full company profileHeXun Biosciences Co., Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
HeXun Biosciences Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 49.5M | 131M | 286M | 293M | 333M |
| Gross Profit | 0.00 | 44.6M | 114M | 261M | 266M | 309M |
| Operating Income | -50.7M | -3.55M | 27.4M | 156M | 118M | 165M |
| EBITDA | -29.5M | 11.2M | 55.6M | 186M | 156M | 205M |
| Net Income | -43.0M | -5.19M | 33.5M | 147M | 112M | 132M |
| EPS | -1.41 | -0.14 | 0.89 | 3.20 | 2.43 | 2.52 |
| Balance Sheet | ||||||
| Total Assets | 295M | 404M | 571M | 707M | 837M | 1.18B |
| Total Liabilities | 79.9M | 89.3M | 98.1M | 86.3M | 95.5M | 110M |
| Shareholders' Equity | 215M | 315M | 473M | 621M | 742M | 1.07B |
| Cash & Short-term Investments | 85.0M | 192M | 330M | 373M | 208M | 418M |
| Total Debt | 74.1M | 69.4M | 70.1M | 35.0M | - | - |
| Cash Flow | ||||||
| Operating Cash Flow | -35.5M | 11.2M | 43.1M | 121M | 164M | 134M |
| Capital Expenditure | 0.00 | 1.23M | 22.8M | 37.3M | 28.9M | 27.2M |
| Free Cash Flow | -35.5M | 10.0M | 20.3M | 83.6M | 135M | 107M |
| Ratios | ||||||
| ROE | -20.0% | -1.6% | 7.1% | 23.7% | 15.1% | 12.3% |
| ROA | -14.6% | -1.3% | 5.9% | 20.8% | 13.4% | 11.2% |
| Net Profit Margin | - | -10.5% | 25.6% | 51.4% | 38.2% | 39.5% |
| Debt to Equity | 0.35x | 0.22x | 0.15x | 0.06x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
HeXun Biosciences Co., Ltd. dividends
- Dividend yield
- 0.46%
- Forward dividend
- 0.19 TWD
- Payout ratio
- -
- Ex-dividend date
- Aug 18, 2026
Who owns HeXun Biosciences Co., Ltd.
- Insiders 39.58%
- Institutions 0.00%
- Public & others 60.42%
- Shares outstanding 51.1M
- Free float 35.9M
HeXun Biosciences Co., Ltd. company profile
- Company name
- HeXun Biosciences Co., Ltd.
- Ticker
- 6986.TWO
- ISIN
- TW0006986003
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 53
- Fiscal year end
- December
- Address
- No. 1490, Chunri Road, Taoyuan City, Taiwan, 33022
- Phone
- 886 3 317 5088
- Website
- hexunbio.com
About HeXun Biosciences Co., Ltd.
HeXun Biosciences Co., Ltd. engages in the research and development of stem cell drug development and cardiovascular disease treatments in Taiwan. It provides contract manufacturing; commissioned inspection; aseptic filling; and consulting services. The company was founded in 2019 and is based in Taoyuan City, Taiwan.
HeXun Biosciences Co., Ltd. management
4- Mr. Ji-Hong HuangPresident & Chairman
- Yushen LanAccounting & Finance Director
- Arvin ChenVice President of Technology Management
- Fred ChengDirector of Administration